Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Pacific Biomarkers' Dr. Amar A. Sethi Recognized by R&D Directions as One of Nine "Most Notable People in R&D"

Published: Thursday, March 03, 2011
Last Updated: Thursday, March 03, 2011
Bookmark and Share
Vice President of R&D singled out for work in seeking clues to heart-disease risk.

Pacific Biomarkers, Inc., a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has announced that Amar A. Sethi, MD, PhD, the Company's Vice President of Research and Development, has been named as one of R&D Directions' "Most Notable People in R&D."

"We are very pleased and proud that Amar has been recognized with this distinguished honor. He has been an extremely valuable member of our team and has been instrumental in advancing our biomarker development programs for cardiovascular disease and kidney injury," said Ron Helm, PBI's Chairman and Chief Executive Officer.

Helm continued, "PBI is committed to scientific and commercial excellence as our fundamental mission to develop novel biomarkers, and Amar's leadership in spearheading our efforts exemplifies this commitment."

"I am sincerely honored to be recognized by R&D Directions," said Dr. Sethi. "I continue to be fortunate to now have so many enriching opportunities in R&D, and I am particularly grateful for helping to leverage my years of experience in biomarker research toward PBI's specific research initiatives."

R&D Directions' selection of the "Most Notable People in R&D" pays tribute to those who have made significant breakthroughs in the discovery and development of drugs that indelibly change the ways in which particular diseases are treated.

Dr. Sethi's entire career has been oriented toward analyzing markers in the human body that indicate the presence of specific ailments. After receiving his PhD in genetic epidemiology at the University of Copenhagen School of Medicine, he undertook postdoctoral research at Copenhagen University Hospital. There he investigated the genetic variation of the liver x-receptor and the beta-2 adrenergic receptor genes and their potential associations with cardiovascular diseases.

Later, as an NIH postdoc, he focused on such topics as the compositional and functional properties of HDL in patients with ischemic heart disease, and the characterization and function of new Apo-AI mimetic peptides potentially to be used as HDL-C raising compounds.

Last year, Dr. Sethi was lead author on a research study published in Clinical Chemistry that identified the potential use of two diagnostic markers for ischemic heart disease. Individuals with ischemic heart disease and either high or low HDL-cholesterol levels were compared with subjects without ischemic heart disease. The study found that pre-beta1 HDL concentrations were twice as high in individuals with ischemic heart disease as compared to those with no heart disease. This was true in both the high and low HDL-cholesterol groups.

The patients with elevated pre-beta1 HDL levels also had low LCAT, an enzyme important for removing excess cholesterol levels. Measuring both pre-beta1 HDL and LCAT, the authors were able to correctly classify subjects with ischemic heart disease in more than 90% of the cases. Thus, pre-beta1 HDL concentrations and LCAT activity levels are potentially useful diagnostic markers for ischemic heart disease.

In addition to his work on cardiovascular disease, Sethi is helping to lead Pacific Biomarkers’ Kidney Injury Biomarker Initiative. It is anticipated that new kidney safety biomarkers will be developed to the point of use in clinical trials and ultimately as a basis of more accurate and powerful IVDs that could replace existing standard tests that are >60 years old. The initiative aims to identify the biological, analytical and clinical qualities of the markers via collaboration with several clients.

To date, the analytical performance for some of the markers has already been characterized, while validation of others is still in progress. A chief goal will be to find the methods and testing platforms that produce superior precision, accuracy, sensitivity and specificity.

The range of potential IVD tests making use of these markers includes one that could assist physicians who need general information about acute kidney injury; a test for use in the emergency room leading up to a kidney transplant; and a test to follow the progress of diabetic patients, a population prone to kidney disease.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pacific Biomarkers CSO Elizabeth T. Leary Co-Authors Paper in March Issue of Clinical Chemistry
Article explores the contribution of assay methodologies in risk classification for cardiovascular disease.
Wednesday, March 09, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos